Board of Directors

Sandeep Laumas, M.D.
Executive Chairman and Chief Executive Officer
Sandeep Laumas
Dr. Laumas joined Private Innovate in 2014 as its executive chairman and as a member of its board of directors, and became our executive chairman and a member of our board of directors in connection with the completion of the Merger. In August 2007, Dr. Laumas founded Bearing Circle Capital, LP, an investment partnership, and has served as its managing director since such time. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs Dr. Laumas moved to the buy side as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a managing director of North Sound Capital from 2003 to 2007, where he was responsible for the global healthcare investment portfolio. From February 2011 to 2012, he was a member of the board of directors of Super Religare Laboratories Limited, Southeast Asia’s largest clinical laboratory service company. Dr. Laumas serves as an independent director on the board of directors of BioXcel Therapeutics, Inc. (Nasdaq: BTAI) and also served as a director of Parkway Holdings Ltd. (acquired by IHH Healthcare for $3 Billion: Singapore: IHH) from May through August 2010. Dr. Laumas received his A.B. in chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995, with a research gap year at the Dana-Farber Cancer Institute, and completed his medical internship in 1996 from the Yale University School of Medicine. We believe that Dr. Laumas’s prior board service and years of experience investing in the healthcare industry qualifies Dr. Laumas to serve on our board of directors.
Chairman of the Board
Jay P. Madan, M.S.
Founder, President and Chief Business Officer
Jay P. Madan
Mr. Madan founded Private Innovate in 2012 and began serving as its president and as a member of its board of directors at such time, and he became our president and a member of our board of directors in connection with the completion of the Merger. In March 2018, Mr. Madan was also appointed as our chief business officer and serves as our interim principal financial officer and interim principal accounting officer. Prior to founding Private Innovate, Mr. Madan was an independent contractor advising multiple life sciences companies, including Reliance Life Sciences, Millipore, Baxter, Dade Behring and Goodwin. This experience in working across multiple teams led him to develop a global network of healthcare professionals. From July 2007 to November 2008, Mr. Madan served as the vice president of business development at Reliance Biopharmaceuticals Pvt. Ltd., a part of Reliance Industries Ltd., India's largest conglomerate. While at Reliance and Goodwin, Mr. Madan was focused on the development of their contract manufacturing businesses. Mr. Madan holds a B.S. in chemical engineering from University of Mumbai and an M.S. in chemical engineering from Washington State University. We believe that Mr. Madan's role as a founder of lnnovate and extensive experience in the life sciences and biotech industries qualifies him to serve on our board of directors.
Financial Expert
Lorin K. Johnson, Ph.D.
Lorin K. Johnson

Dr. Johnson joined our board of directors in January 2018. He is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company, and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as director of scientific operations and chief scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of Glycyx MOR, LTD and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, Intact Inc., a GI specialty drug delivery company based in Belmont, CA, Edesa Biotech (Nasdaq: EDSA) a dermatological and GI company based in Ontario, Canada, and Tumour Trace Ltd, a cancer diagnostic company based in Nottingham, UK. In addition to his career in industry, Dr. Johnson has served as an assistant professor of pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco. We believe that Dr. Johnson’s extensive experience in the pharmaceutical and life science industries, both as an executive and investor, qualifies him to serve on our board of directors.

Independent Director
Anthony E. Maida III, PhD, MA, MBA
Anthony E. Maida III

Dr. Maida joined our board of directors in January 2018. He has wide experience in the biotechnology industry for more than two decades serving as a CEO, member of the board of directors and working with biotechnology investors. From 1992 to September of 1999, Dr. Maida was president and chief executive officer of Jenner Biotherapies, Inc., an immunotherapy company. From 1997 through 2010, Dr. Maida served as chairman, founder and director of BioConsul Drug Development Corporation and as principal of Anthony Maida Consulting International, advising pharmaceutical and investment firms in the clinical development of therapeutic products and product/company acquisitions. From June 2009 through June 2010, Dr. Maida served as vice president of clinical research and general manager, oncology, worldwide for PharmaNet, Inc., a clinical research organization. Since June 2010, Dr. Maida has served as senior vice president, clinical research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy for patients with glioblastoma multiforme and prostate cancer. Dr. Maida has served in a number of executive roles, including president and CEO of Replicon NeuroTherapeutics, Inc. Dr. Maida is currently a member of the board of directors and audit chair of Spectrum Pharmaceuticals, Inc. (Nasdaq GS: SPPI) and Vitality Biopharma, Inc. (OTCQB: VBIO) and was formerly a member of the Board of Directors and audit chair of OncoSec Medical Inc. (OTCQB: ONCS). Dr. Maida holds a B.A. in biology and history, an M.B.A., an M.A. in toxicology and a Ph.D. in immunology. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the Society of Neuro-Oncology, the International Society for Biological Therapy of Cancer and the American Chemical Society. We believe that Dr. Maida's extensive experience as an executive at various biotechnology and biopharmaceutical companies and his service on private and public company boards qualifies him to serve on our board of directors.

Independent Director
Roy Proujansky, MD
Roy Proujansky

Dr. Proujansky joined our board of directors in January 2018. He is a pediatric gastroenterologist who, since July 2013, has served as the executive vice president and chief executive of Delaware Valley Operations (DuPont Hospital for Children) for the Nemours Children’s Health System, a non-profit children’s health organization. Before his current position, Dr. Proujansky served as executive vice president for patient operations and chief operating officer of Nemours from 2006 to July 2013. From 2000 to 2006, Dr. Proujansky was the Robert L. Brent professor and chairman of pediatrics and associate dean for Jefferson Medical College at Thomas Jefferson University. Additionally, from 1998 to 2015, Dr. Proujansky was the co-director or direct supervisor of Nemours Research Programs and has authored 47 original publications and book chapters in the field of pediatric gastroenterology. Dr. Proujansky received an M.D. from Northwestern University, an M.B.A. from the University of Massachusetts at Amherst and a B.S. in medical Science from Northwestern University. We believe Dr. Proujansky’s extensive knowledge and experience in the field of pediatric gastroenterology qualifies him to serve on our board of directors.

Independent Director
Saira Ramasastry, M.S. M.Phil.
Saira Ramasastry, M.S.
Ms. Ramasastry has served as a member of our board of directors since June 2018. Since April 2009, she has served as managing partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life science industry. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, and strategic and capital markets transactions. Prior to joining Merrill Lynch, she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the board of directors of biotechnology companies Sangamo Therapeutics Inc., Pain Therapeutics Inc., and Elevian, Inc., on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. Ms. Ramasastry received her B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, and an M. Phil. in management studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. We believe that Ms. Ramasastry’s experience in the life science industry and her experience on public company boards qualifies her to serve on our board of directors.
Independent Director

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy. 

Cookie Policy

Copyright West LLC. Minimum 15 minutes delayed.